Streetbeat News

Regulatory

ETNB

89bio has announced alignment with the FDA and EMA on a Phase 3 program for Pegozafermin, a treatment for Nonalcoholic Steatohepatitis (NASH). The program is set to begin in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 12:05 pm

APLM

Apollomics has presented efficacy and safety data from the ongoing KUNPENG and SPARTA trials of Vebreltinib at the IASLC North America Conference on Lung Cancer. The data is significant for the continued development and potential future approval of Vebreltinib for treating lung cancer.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 12:04 pm

RDHL

RedHill Biopharma has secured approximately $4.8 million in non-dilutive external funding for the Phase 2 study of RHB-107, a COVID-19 treatment. The study, which has FDA clearance, will enroll its first patient soon and is expected to be completed by the end of 2024. It will take place in the U.S., Thailand, Ivory Coast, South Africa, and Uganda.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 12:03 pm

VFS

VinFast Auto (VFS) and the U.S. International Development Financial Corporation (DFC) signed an LOI for a potential $500M loan for a lithium-ion battery facility in Vietnam. This move aligns with sustainable transportation goals and strengthens Vietnam-U.S. relations.

Portfolio Pulse from Charles Gross

December 04, 2023 | 11:56 am

EVLO

Evelo Biosciences (EVLO) received a notification from NASDAQ's Listing Qualifications on December 1, 2023, indicating that due to the events disclosed in its November 21 filing, the staff believes the company no longer has an operating business and is considered a public shell as per the 8-K filing.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 11:18 am

GERN

Geron Corporation announced the publication of results from the IMerge Phase 3 trial of Imetelstat versus placebo in The Lancet. The trial focused on patients with lower-risk Myelodysplastic Syndromes who are relapsed/refractory or ineligible for erythropoiesis-stimulating agents.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 10:02 am

F

GM

STLA

TM

TSLA

The return of United Auto Workers to GM, Ford, and Stellantis is expected to boost US November payrolls by 180,000, a rise from October's 150,000. The unemployment rate is projected to remain at 3.9%, with a 4% increase in average hourly earnings year-over-year. The Federal Reserve is entering a blackout period before their December meeting, with Chair Jerome Powell downplaying rate cut expectations for early 2024. The UAW ended a six-week strike with GM, Ford, and Stellantis, securing a pay raise and cost-of-living allowances, and is now targeting unionization at non-union automakers, including Tesla and Toyota.

Portfolio Pulse from Benzinga Neuro

December 04, 2023 | 7:52 am

CULP

ESTC

GTLB

PATH

SAIC

The S&P 500 reached a new high for 2023, reflecting increased investor sentiment as indicated by the CNN Money Fear and Greed index remaining in the 'Greed' zone. Federal Reserve Chair Jerome Powell signaled a readiness to adjust policies if needed. U.S. construction spending rose, while the ISM manufacturing PMI was unchanged. Elastic N.V. and UiPath Inc. saw significant stock gains after reporting strong financial results. The Dow Jones and Nasdaq also closed higher. Investors are looking forward to earnings from SAIC, Culp, Inc, and GitLab Inc.

Portfolio Pulse from Lisa Levin

December 04, 2023 | 7:04 am

BTCUSD

Ric Edelman, founder of Edelman Financial Services, expressed that financial advisors are eager to offer spot bitcoin ETFs to their clients, pending SEC approval. A survey indicated that 77% of advisors are ready to include spot Bitcoin ETFs in their clients' portfolios, and 47% already hold Bitcoin. Bloomberg ETF analyst Eric Balchunas gave a 90% chance of SEC approval for spot bitcoin ETFs by Jan. 10. Bitcoin's price recently surpassed $40,000, partly due to anticipation of SEC approval for a Bitcoin Spot ETF.

Portfolio Pulse from Benzinga Neuro

December 04, 2023 | 7:03 am

VALN

Valneva has reported that its single-shot Chikungunya vaccine, IXCHIQ®, shows 24-month antibody persistence, indicating long-term effectiveness. This data could potentially support the use of IXCHIQ® in preventing Chikungunya virus infections.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 6:58 am